{"id":37999,"date":"2026-04-27T13:49:51","date_gmt":"2026-04-27T11:49:51","guid":{"rendered":"https:\/\/kymos.com\/?p=37999"},"modified":"2026-04-27T13:55:38","modified_gmt":"2026-04-27T11:55:38","slug":"solutions-tout-en-un-pour-les-etudes-precliniques-de-sante-animale-de-bioequivalence-et-cliniques","status":"publish","type":"post","link":"https:\/\/kymos.com\/fr\/news\/solutions-tout-en-un-pour-les-etudes-precliniques-de-sante-animale-de-bioequivalence-et-cliniques\/","title":{"rendered":"Bioanalyse des cannabino\u00efdes : une m\u00e9thode LC-MS\/MS multi-analyte valid\u00e9e dans le plasma humain"},"content":{"rendered":"<div class=\"fusion-fullwidth fullwidth-box fusion-builder-row-1 fusion-flex-container nonhundred-percent-fullwidth non-hundred-percent-height-scrolling\" style=\"--awb-border-radius-top-left:0px;--awb-border-radius-top-right:0px;--awb-border-radius-bottom-right:0px;--awb-border-radius-bottom-left:0px;--awb-flex-wrap:wrap;\" ><div class=\"fusion-builder-row fusion-row fusion-flex-align-items-flex-start fusion-flex-content-wrap\" style=\"max-width:calc( 1170px + 20px );margin-left: calc(-20px \/ 2 );margin-right: calc(-20px \/ 2 );\"><div class=\"fusion-layout-column fusion_builder_column fusion-builder-column-0 fusion_builder_column_1_1 1_1 fusion-flex-column\" style=\"--awb-bg-size:cover;--awb-width-large:100%;--awb-margin-top-large:0px;--awb-spacing-right-large:10px;--awb-margin-bottom-large:0px;--awb-spacing-left-large:10px;--awb-width-medium:100%;--awb-spacing-right-medium:10px;--awb-spacing-left-medium:10px;--awb-width-small:100%;--awb-spacing-right-small:10px;--awb-spacing-left-small:10px;\"><div class=\"fusion-column-wrapper fusion-flex-justify-content-flex-start fusion-content-layout-column\"><div class=\"fusion-text fusion-text-1\"><p><span style=\"font-size: 14pt;\">L\u2019<strong>int\u00e9r\u00eat croissant pour les th\u00e9rapies \u00e0 base de cannabino\u00efdes<\/strong> a entra\u00een\u00e9 une <strong>demande accrue de m\u00e9thodes bioanalytiques robustes et fiables, capables de soutenir les programmes de d\u00e9veloppement de m\u00e9dicaments<\/strong>. Au-del\u00e0 de la quantification des compos\u00e9s parents tels que le cannabidiol (CBD) et le t\u00e9trahydrocannabinol (THC), il existe un <strong>besoin clair de surveiller avec pr\u00e9cision leurs principaux m\u00e9tabolites afin de mieux caract\u00e9riser la pharmacocin\u00e9tique, la biodisponibilit\u00e9 et l\u2019exposition globale aux m\u00e9dicaments<\/strong>. <\/span><\/p>\n<p><span style=\"font-size: 14pt;\">Cependant, la d\u00e9termination simultan\u00e9e de plusieurs cannabino\u00efdes et de leurs m\u00e9tabolites dans les matrices biologiques pr\u00e9sente des d\u00e9fis analytiques importants. Dans ce contexte, Kymos <a href=\"https:\/\/kymos.com\/fr\/news\/une-methode-lc-ms-ms-pour-quatre-cannabinoides\/\" data-wpel-link=\"internal\">a encore \u00e9largi son expertise<\/a> en bioanalyse des cannabino\u00efdes gr\u00e2ce au <strong>d\u00e9veloppement et \u00e0 la validation d\u2019une m\u00e9thode LC-MS\/MS sensible et robuste pour la quantification simultan\u00e9e de six analytes cl\u00e9s, y compris le CBD, le THC et leurs principaux m\u00e9tabolites dans le plasma humain.<\/strong> <\/span><\/p>\n<h2><strong>D\u00e9fis analytiques en bioanalyse des cannabino\u00efdes<\/strong><\/h2>\n<p><span style=\"font-size: 14pt;\">La bioanalyse des cannabino\u00efdes est intrins\u00e8quement complexe en raison de plusieurs facteurs. <strong>Ces compos\u00e9s sont g\u00e9n\u00e9ralement pr\u00e9sents \u00e0 de faibles concentrations, ce qui n\u00e9cessite des techniques analytiques tr\u00e8s sensibles<\/strong>. De plus, la similitude structurelle entre les compos\u00e9s parents et leurs m\u00e9tabolites exige une <strong>s\u00e9lectivit\u00e9 \u00e9lev\u00e9e pour garantir une quantification pr\u00e9cise<\/strong>. <\/span><\/p>\n<p><span style=\"font-size: 14pt;\">Un autre d\u00e9fi majeur r\u00e9side dans la <strong>n\u00e9cessit\u00e9 de couvrir une large gamme dynamique de concentrations au sein d\u2019une seule m\u00e9thode<\/strong>, en particulier lorsque les compos\u00e9s parents et les m\u00e9tabolites sont inclus. En outre, les matrices biologiques telles que le plasma humain introduisent des interf\u00e9rences potentielles, rendant la <strong>pr\u00e9paration efficace des \u00e9chantillons essentielle<\/strong>. <\/span><\/p>\n<p><span style=\"font-size: 14pt;\">Enfin, les attentes r\u00e9glementaires ont \u00e9volu\u00e9, avec des lignes directrices telles que l\u2019<strong>ICH M10 \u00e9tablissant des exigences claires pour la validation des m\u00e9thodes bioanalytiques<\/strong>, renfor\u00e7ant le besoin de m\u00e9thodologies robustes, reproductibles et conformes.<\/span><\/p>\n<h2><strong>Pr\u00e9sentation de la m\u00e9thode<\/strong><\/h2>\n<h3><strong>Analytes cibles et plages d\u2019\u00e9talonnage<\/strong><\/h3>\n<p><span style=\"font-size: 14pt;\">La m\u00e9thode d\u00e9velopp\u00e9e permet la quantification simultan\u00e9e de six analytes, y compris les compos\u00e9s parents et leurs principaux m\u00e9tabolites :<\/span><\/p>\n<ul>\n<li><span style=\"font-size: 14pt;\"><strong>CBD<\/strong> : 0,5\u2013100 ng\/mL<\/span><\/li>\n<li><span style=\"font-size: 14pt;\"><strong>7-OH-CBD<\/strong> : 0,5\u201350 ng\/mL<\/span><\/li>\n<li><span style=\"font-size: 14pt;\"><strong>7-COOH-CBD<\/strong> : 0,5\u2013500 ng\/mL<\/span><\/li>\n<li><span style=\"font-size: 14pt;\"><strong>THC<\/strong> : 0,5\u2013100 ng\/mL<\/span><\/li>\n<li><span style=\"font-size: 14pt;\"><strong>11-OH-THC<\/strong> : 0,5\u201350 ng\/mL<\/span><\/li>\n<li><span style=\"font-size: 14pt;\"><strong>11-COOH-THC<\/strong> : 0,5\u2013500 ng\/mL<\/span><\/li>\n<\/ul>\n<p><span style=\"font-size: 14pt;\">Cette <strong>large plage d\u2019\u00e9talonnage<\/strong> permet \u00e0 la m\u00e9thode de couvrir les concentrations typiquement observ\u00e9es dans les \u00e9tudes cliniques, soutenant des \u00e9valuations pharmacocin\u00e9tiques compl\u00e8tes.<\/span><\/p>\n<h3><strong>Strat\u00e9gie de pr\u00e9paration des \u00e9chantillons<\/strong><\/h3>\n<p><span style=\"font-size: 14pt;\">La pr\u00e9paration des \u00e9chantillons est bas\u00e9e sur <strong>200 \u00b5L de plasma humain<\/strong> en utilisant du <strong>K\u2082EDTA comme anticoagulant<\/strong>. Une \u00e9tape de pr\u00e9cipitation des prot\u00e9ines avec de l\u2019ac\u00e9tonitrile est appliqu\u00e9e, suivie d\u2019une <strong>filtration \u00e0 l\u2019aide de plaques 96 puits Phree\u2122 Phospholipid Removal<\/strong>. <\/span><\/p>\n<p><span style=\"font-size: 14pt;\">Cette approche assure une \u00e9limination efficace des phospholipides et autres composants de la matrice, am\u00e9liorant la <strong>robustesse de la m\u00e9thode et minimisant les effets de matrice, tout en \u00e9tant adapt\u00e9e \u00e0 l\u2019analyse \u00e0 haut d\u00e9bit<\/strong>.<\/span><\/p>\n<h3><strong>Analyse instrumentale<\/strong><\/h3>\n<p><span style=\"font-size: 14pt;\"><strong>La quantification de tous les analytes est r\u00e9alis\u00e9e par LC-MS\/MS, permettant une sensibilit\u00e9 et une s\u00e9lectivit\u00e9 \u00e9lev\u00e9es.<\/strong> La m\u00e9thode est con\u00e7ue pour assurer une d\u00e9tection fiable de tous les compos\u00e9s au cours d\u2019une seule s\u00e9rie d\u2019analyses, soutenant une analyse multi-analyte efficace.<\/span><\/p>\n<p><span style=\"font-size: 14pt;\">Le syst\u00e8me est <strong>bas\u00e9 sur un spectrom\u00e8tre de masse Triple Quad 6500+ (Sciex), \u00e9quip\u00e9 d\u2019une source d\u2019ions TurboIonSpray,<\/strong> offrant la sensibilit\u00e9 et la robustesse requises pour la quantification des cannabino\u00efdes et de leurs m\u00e9tabolites sur une large gamme de concentrations.<\/span><\/p>\n<h2><strong>Validation de la m\u00e9thode selon l\u2019ICH M10<\/strong><\/h2>\n<p><span style=\"font-size: 14pt;\">La <strong>m\u00e9thode a \u00e9t\u00e9 enti\u00e8rement valid\u00e9e selon les Bonnes Pratiques de Laboratoire (BPL) conform\u00e9ment \u00e0 la ligne directrice ICH M10<\/strong>. La validation a confirm\u00e9 que la <strong>m\u00e9thode est s\u00e9lective, lin\u00e9aire et conforme aux exigences bioanalytiques en mati\u00e8re de pr\u00e9cision, d\u2019exactitude et d\u2019effets de matrice.<\/strong> La stabilit\u00e9, le report et l\u2019aptitude au haut d\u00e9bit ont \u00e9galement \u00e9t\u00e9 d\u00e9montr\u00e9s, garantissant une analyse fiable dans les \u00e9tudes r\u00e9glement\u00e9es. La <strong>m\u00e9thode atteint une limite inf\u00e9rieure de quantification (LLOQ) de 0,5 ng\/mL pour tous les analytes<\/strong>. <\/span><\/p>\n<h2><strong>Principaux atouts de la m\u00e9thode<\/strong><\/h2>\n<ul>\n<li><span style=\"font-size: 14pt;\"><strong>Quantification simultan\u00e9e de six cannabino\u00efdes<\/strong> et m\u00e9tabolites au sein d\u2019une seule m\u00e9thode<\/span><\/li>\n<li><span style=\"font-size: 14pt;\"><strong>Larges plages d\u2019\u00e9talonnage<\/strong> couvrant \u00e0 la fois les compos\u00e9s parents et les m\u00e9tabolites<\/span><\/li>\n<li><span style=\"font-size: 14pt;\">Haute sensibilit\u00e9, avec une <strong>LLOQ de 0,5 ng\/mL<\/strong><\/span><\/li>\n<li><span style=\"font-size: 14pt;\">Pr\u00e9paration des \u00e9chantillons efficace et <strong>robuste<\/strong><\/span><\/li>\n<li><strong><span style=\"font-size: 14pt;\">Enti\u00e8rement valid\u00e9e selon les BPL en conformit\u00e9 avec l\u2019ICH M10<\/span><\/strong><\/li>\n<\/ul>\n<h2><strong>Applications dans le d\u00e9veloppement de m\u00e9dicaments<\/strong><\/h2>\n<p><span style=\"font-size: 14pt;\">Cette m\u00e9thode est bien adapt\u00e9e pour <strong>soutenir un large \u00e9ventail d\u2019\u00e9tudes impliquant des compos\u00e9s \u00e0 base de cannabino\u00efdes<\/strong>, y compris :<\/span><\/p>\n<ul>\n<li><span style=\"font-size: 14pt;\">\u00c9tudes pharmacocin\u00e9tiques<\/span><\/li>\n<li><span style=\"font-size: 14pt;\">Essais cliniques (Phases I\u2013IV)<\/span><\/li>\n<li><span style=\"font-size: 14pt;\">\u00c9tudes de biodisponibilit\u00e9 et de bio\u00e9quivalence<\/span><\/li>\n<li><span style=\"font-size: 14pt;\">\u00e9tudes sur les interactions m\u00e9dicamenteuses<\/span><\/li>\n<\/ul>\n<p><span style=\"font-size: 14pt;\">Sa capacit\u00e9 \u00e0 quantifier simultan\u00e9ment plusieurs analytes la rend particuli\u00e8rement <strong>pr\u00e9cieuse pour une \u00e9valuation compl\u00e8te de l\u2019exposition et le profilage des m\u00e9tabolites en milieu clinique.<\/strong><\/span><\/p>\n<h2><strong>Conclusion<\/strong><\/h2>\n<p><span style=\"font-size: 14pt;\">Une bioanalyse fiable des cannabino\u00efdes exige un \u00e9quilibre pr\u00e9cis entre une sensibilit\u00e9 \u00e9lev\u00e9e et une s\u00e9lectivit\u00e9 rigoureuse. En relevant directement ces d\u00e9fis, <strong>cette m\u00e9thode LC-MS\/MS valid\u00e9e pour six analytes offre une solution conforme aux BPL pour le profilage simultan\u00e9 des m\u00e9tabolites dans le plasma humain.<\/strong> <\/span><\/p>\n<p><span style=\"font-size: 14pt;\">La capacit\u00e9 \u00e0 <strong>suivre \u00e0 la fois les compos\u00e9s parents et leurs principaux m\u00e9tabolites en une seule analyse rationalise les flux de travail cliniques et garantit l\u2019int\u00e9grit\u00e9 des donn\u00e9es<\/strong> requise pour le d\u00e9veloppement de m\u00e9dicaments modernes. Cette capacit\u00e9 \u00e9tendue fournit le soutien bioanalytique robuste n\u00e9cessaire en pharmacocin\u00e9tique des cannabino\u00efdes et pour les soumissions r\u00e9glementaires. <\/span><\/p>\n<p><span style=\"font-size: 14pt;\">Pour plus d\u2019informations sur la mani\u00e8re dont ces m\u00e9thodes valid\u00e9es peuvent soutenir vos programmes cliniques ou pour discuter d\u2019une strat\u00e9gie bioanalytique personnalis\u00e9e, veuillez contacter notre \u00e9quipe technique \u00e0 l\u2019adresse <a href=\"https:\/\/kymos.com\/fr\/contact\/\" data-wpel-link=\"internal\">https:\/\/kymos.com\/contact<\/a><\/span><\/p>\n<\/div><\/div><\/div><\/div><\/div>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":8,"featured_media":38006,"comment_status":"closed","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[257,375],"tags":[],"class_list":["post-37999","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-bioanalyse","category-general"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Bioanalyse des cannabino\u00efdes : m\u00e9thode LC-MS\/MS valid\u00e9e pour 6 analytes<\/title>\n<meta name=\"description\" content=\"Six cannabino\u00efdes, une m\u00e9thode : analyse LC-MS\/MS valid\u00e9e avec une sensibilit\u00e9 et une s\u00e9lectivit\u00e9 \u00e9lev\u00e9es chez Kymos Group.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/kymos.com\/fr\/news\/solutions-tout-en-un-pour-les-etudes-precliniques-de-sante-animale-de-bioequivalence-et-cliniques\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Bioanalyse des cannabino\u00efdes : m\u00e9thode LC-MS\/MS valid\u00e9e pour 6 analytes\" \/>\n<meta property=\"og:description\" content=\"Six cannabino\u00efdes, une m\u00e9thode : analyse LC-MS\/MS valid\u00e9e avec une sensibilit\u00e9 et une s\u00e9lectivit\u00e9 \u00e9lev\u00e9es chez Kymos Group.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/kymos.com\/fr\/news\/solutions-tout-en-un-pour-les-etudes-precliniques-de-sante-animale-de-bioequivalence-et-cliniques\/\" \/>\n<meta property=\"og:site_name\" content=\"Kymos\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-27T11:49:51+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-27T11:55:38+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/kymos.com\/wp-content\/uploads\/2026\/04\/Cannabinoid-Bioanalysis-6Analyte-Method-Header.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1600\" \/>\n\t<meta property=\"og:image:height\" content=\"900\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Sandra Magdaleno\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@KymosGroup\" \/>\n<meta name=\"twitter:site\" content=\"@KymosGroup\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"Sandra Magdaleno\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/kymos.com\\\/fr\\\/news\\\/solutions-tout-en-un-pour-les-etudes-precliniques-de-sante-animale-de-bioequivalence-et-cliniques\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/kymos.com\\\/fr\\\/news\\\/solutions-tout-en-un-pour-les-etudes-precliniques-de-sante-animale-de-bioequivalence-et-cliniques\\\/\"},\"author\":{\"name\":\"Sandra Magdaleno\",\"@id\":\"https:\\\/\\\/kymos.com\\\/fr\\\/#\\\/schema\\\/person\\\/b0ed444c71c4c8afa6f4ae674967c999\"},\"headline\":\"Bioanalyse des cannabino\u00efdes : une m\u00e9thode LC-MS\\\/MS multi-analyte valid\u00e9e dans le plasma humain\",\"datePublished\":\"2026-04-27T11:49:51+00:00\",\"dateModified\":\"2026-04-27T11:55:38+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/kymos.com\\\/fr\\\/news\\\/solutions-tout-en-un-pour-les-etudes-precliniques-de-sante-animale-de-bioequivalence-et-cliniques\\\/\"},\"wordCount\":1296,\"image\":{\"@id\":\"https:\\\/\\\/kymos.com\\\/fr\\\/news\\\/solutions-tout-en-un-pour-les-etudes-precliniques-de-sante-animale-de-bioequivalence-et-cliniques\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/kymos.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/Cannabinoid-Bioanalysis-6Analyte-Method-Header.png\",\"articleSection\":[\"Bioanalyse\",\"G\u00e9n\u00e9ral\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/kymos.com\\\/fr\\\/news\\\/solutions-tout-en-un-pour-les-etudes-precliniques-de-sante-animale-de-bioequivalence-et-cliniques\\\/\",\"url\":\"https:\\\/\\\/kymos.com\\\/fr\\\/news\\\/solutions-tout-en-un-pour-les-etudes-precliniques-de-sante-animale-de-bioequivalence-et-cliniques\\\/\",\"name\":\"Bioanalyse des cannabino\u00efdes : m\u00e9thode LC-MS\\\/MS valid\u00e9e pour 6 analytes\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/kymos.com\\\/fr\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/kymos.com\\\/fr\\\/news\\\/solutions-tout-en-un-pour-les-etudes-precliniques-de-sante-animale-de-bioequivalence-et-cliniques\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/kymos.com\\\/fr\\\/news\\\/solutions-tout-en-un-pour-les-etudes-precliniques-de-sante-animale-de-bioequivalence-et-cliniques\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/kymos.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/Cannabinoid-Bioanalysis-6Analyte-Method-Header.png\",\"datePublished\":\"2026-04-27T11:49:51+00:00\",\"dateModified\":\"2026-04-27T11:55:38+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/kymos.com\\\/fr\\\/#\\\/schema\\\/person\\\/b0ed444c71c4c8afa6f4ae674967c999\"},\"description\":\"Six cannabino\u00efdes, une m\u00e9thode : analyse LC-MS\\\/MS valid\u00e9e avec une sensibilit\u00e9 et une s\u00e9lectivit\u00e9 \u00e9lev\u00e9es chez Kymos Group.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/kymos.com\\\/fr\\\/news\\\/solutions-tout-en-un-pour-les-etudes-precliniques-de-sante-animale-de-bioequivalence-et-cliniques\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/kymos.com\\\/fr\\\/news\\\/solutions-tout-en-un-pour-les-etudes-precliniques-de-sante-animale-de-bioequivalence-et-cliniques\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/kymos.com\\\/fr\\\/news\\\/solutions-tout-en-un-pour-les-etudes-precliniques-de-sante-animale-de-bioequivalence-et-cliniques\\\/#primaryimage\",\"url\":\"https:\\\/\\\/kymos.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/Cannabinoid-Bioanalysis-6Analyte-Method-Header.png\",\"contentUrl\":\"https:\\\/\\\/kymos.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/Cannabinoid-Bioanalysis-6Analyte-Method-Header.png\",\"width\":1600,\"height\":900},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/kymos.com\\\/fr\\\/news\\\/solutions-tout-en-un-pour-les-etudes-precliniques-de-sante-animale-de-bioequivalence-et-cliniques\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/kymos.com\\\/fr\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Bioanalyse des cannabino\u00efdes : une m\u00e9thode LC-MS\\\/MS multi-analyte valid\u00e9e dans le plasma humain\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/kymos.com\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/kymos.com\\\/fr\\\/\",\"name\":\"Kymos Group\",\"description\":\"Kymos Group\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/kymos.com\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/kymos.com\\\/fr\\\/#\\\/schema\\\/person\\\/b0ed444c71c4c8afa6f4ae674967c999\",\"name\":\"Sandra Magdaleno\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/bc2f5bf2cac304990fdc84e9a3ed0b47c89ed981aaa966dfb2f3c3f39f531df6?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/bc2f5bf2cac304990fdc84e9a3ed0b47c89ed981aaa966dfb2f3c3f39f531df6?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/bc2f5bf2cac304990fdc84e9a3ed0b47c89ed981aaa966dfb2f3c3f39f531df6?s=96&d=mm&r=g\",\"caption\":\"Sandra Magdaleno\"},\"url\":\"https:\\\/\\\/kymos.com\\\/fr\\\/news\\\/author\\\/sandra-magdaleno\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Bioanalyse des cannabino\u00efdes : m\u00e9thode LC-MS\/MS valid\u00e9e pour 6 analytes","description":"Six cannabino\u00efdes, une m\u00e9thode : analyse LC-MS\/MS valid\u00e9e avec une sensibilit\u00e9 et une s\u00e9lectivit\u00e9 \u00e9lev\u00e9es chez Kymos Group.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/kymos.com\/fr\/news\/solutions-tout-en-un-pour-les-etudes-precliniques-de-sante-animale-de-bioequivalence-et-cliniques\/","og_locale":"fr_FR","og_type":"article","og_title":"Bioanalyse des cannabino\u00efdes : m\u00e9thode LC-MS\/MS valid\u00e9e pour 6 analytes","og_description":"Six cannabino\u00efdes, une m\u00e9thode : analyse LC-MS\/MS valid\u00e9e avec une sensibilit\u00e9 et une s\u00e9lectivit\u00e9 \u00e9lev\u00e9es chez Kymos Group.","og_url":"https:\/\/kymos.com\/fr\/news\/solutions-tout-en-un-pour-les-etudes-precliniques-de-sante-animale-de-bioequivalence-et-cliniques\/","og_site_name":"Kymos","article_published_time":"2026-04-27T11:49:51+00:00","article_modified_time":"2026-04-27T11:55:38+00:00","og_image":[{"width":1600,"height":900,"url":"https:\/\/kymos.com\/wp-content\/uploads\/2026\/04\/Cannabinoid-Bioanalysis-6Analyte-Method-Header.png","type":"image\/png"}],"author":"Sandra Magdaleno","twitter_card":"summary_large_image","twitter_creator":"@KymosGroup","twitter_site":"@KymosGroup","twitter_misc":{"\u00c9crit par":"Sandra Magdaleno","Dur\u00e9e de lecture estim\u00e9e":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/kymos.com\/fr\/news\/solutions-tout-en-un-pour-les-etudes-precliniques-de-sante-animale-de-bioequivalence-et-cliniques\/#article","isPartOf":{"@id":"https:\/\/kymos.com\/fr\/news\/solutions-tout-en-un-pour-les-etudes-precliniques-de-sante-animale-de-bioequivalence-et-cliniques\/"},"author":{"name":"Sandra Magdaleno","@id":"https:\/\/kymos.com\/fr\/#\/schema\/person\/b0ed444c71c4c8afa6f4ae674967c999"},"headline":"Bioanalyse des cannabino\u00efdes : une m\u00e9thode LC-MS\/MS multi-analyte valid\u00e9e dans le plasma humain","datePublished":"2026-04-27T11:49:51+00:00","dateModified":"2026-04-27T11:55:38+00:00","mainEntityOfPage":{"@id":"https:\/\/kymos.com\/fr\/news\/solutions-tout-en-un-pour-les-etudes-precliniques-de-sante-animale-de-bioequivalence-et-cliniques\/"},"wordCount":1296,"image":{"@id":"https:\/\/kymos.com\/fr\/news\/solutions-tout-en-un-pour-les-etudes-precliniques-de-sante-animale-de-bioequivalence-et-cliniques\/#primaryimage"},"thumbnailUrl":"https:\/\/kymos.com\/wp-content\/uploads\/2026\/04\/Cannabinoid-Bioanalysis-6Analyte-Method-Header.png","articleSection":["Bioanalyse","G\u00e9n\u00e9ral"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/kymos.com\/fr\/news\/solutions-tout-en-un-pour-les-etudes-precliniques-de-sante-animale-de-bioequivalence-et-cliniques\/","url":"https:\/\/kymos.com\/fr\/news\/solutions-tout-en-un-pour-les-etudes-precliniques-de-sante-animale-de-bioequivalence-et-cliniques\/","name":"Bioanalyse des cannabino\u00efdes : m\u00e9thode LC-MS\/MS valid\u00e9e pour 6 analytes","isPartOf":{"@id":"https:\/\/kymos.com\/fr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/kymos.com\/fr\/news\/solutions-tout-en-un-pour-les-etudes-precliniques-de-sante-animale-de-bioequivalence-et-cliniques\/#primaryimage"},"image":{"@id":"https:\/\/kymos.com\/fr\/news\/solutions-tout-en-un-pour-les-etudes-precliniques-de-sante-animale-de-bioequivalence-et-cliniques\/#primaryimage"},"thumbnailUrl":"https:\/\/kymos.com\/wp-content\/uploads\/2026\/04\/Cannabinoid-Bioanalysis-6Analyte-Method-Header.png","datePublished":"2026-04-27T11:49:51+00:00","dateModified":"2026-04-27T11:55:38+00:00","author":{"@id":"https:\/\/kymos.com\/fr\/#\/schema\/person\/b0ed444c71c4c8afa6f4ae674967c999"},"description":"Six cannabino\u00efdes, une m\u00e9thode : analyse LC-MS\/MS valid\u00e9e avec une sensibilit\u00e9 et une s\u00e9lectivit\u00e9 \u00e9lev\u00e9es chez Kymos Group.","breadcrumb":{"@id":"https:\/\/kymos.com\/fr\/news\/solutions-tout-en-un-pour-les-etudes-precliniques-de-sante-animale-de-bioequivalence-et-cliniques\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/kymos.com\/fr\/news\/solutions-tout-en-un-pour-les-etudes-precliniques-de-sante-animale-de-bioequivalence-et-cliniques\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/kymos.com\/fr\/news\/solutions-tout-en-un-pour-les-etudes-precliniques-de-sante-animale-de-bioequivalence-et-cliniques\/#primaryimage","url":"https:\/\/kymos.com\/wp-content\/uploads\/2026\/04\/Cannabinoid-Bioanalysis-6Analyte-Method-Header.png","contentUrl":"https:\/\/kymos.com\/wp-content\/uploads\/2026\/04\/Cannabinoid-Bioanalysis-6Analyte-Method-Header.png","width":1600,"height":900},{"@type":"BreadcrumbList","@id":"https:\/\/kymos.com\/fr\/news\/solutions-tout-en-un-pour-les-etudes-precliniques-de-sante-animale-de-bioequivalence-et-cliniques\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/kymos.com\/fr\/"},{"@type":"ListItem","position":2,"name":"Bioanalyse des cannabino\u00efdes : une m\u00e9thode LC-MS\/MS multi-analyte valid\u00e9e dans le plasma humain"}]},{"@type":"WebSite","@id":"https:\/\/kymos.com\/fr\/#website","url":"https:\/\/kymos.com\/fr\/","name":"Kymos Group","description":"Kymos Group","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/kymos.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Person","@id":"https:\/\/kymos.com\/fr\/#\/schema\/person\/b0ed444c71c4c8afa6f4ae674967c999","name":"Sandra Magdaleno","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/secure.gravatar.com\/avatar\/bc2f5bf2cac304990fdc84e9a3ed0b47c89ed981aaa966dfb2f3c3f39f531df6?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/bc2f5bf2cac304990fdc84e9a3ed0b47c89ed981aaa966dfb2f3c3f39f531df6?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/bc2f5bf2cac304990fdc84e9a3ed0b47c89ed981aaa966dfb2f3c3f39f531df6?s=96&d=mm&r=g","caption":"Sandra Magdaleno"},"url":"https:\/\/kymos.com\/fr\/news\/author\/sandra-magdaleno\/"}]}},"_links":{"self":[{"href":"https:\/\/kymos.com\/fr\/wp-json\/wp\/v2\/posts\/37999","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/kymos.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/kymos.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/kymos.com\/fr\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/kymos.com\/fr\/wp-json\/wp\/v2\/comments?post=37999"}],"version-history":[{"count":6,"href":"https:\/\/kymos.com\/fr\/wp-json\/wp\/v2\/posts\/37999\/revisions"}],"predecessor-version":[{"id":38088,"href":"https:\/\/kymos.com\/fr\/wp-json\/wp\/v2\/posts\/37999\/revisions\/38088"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/kymos.com\/fr\/wp-json\/wp\/v2\/media\/38006"}],"wp:attachment":[{"href":"https:\/\/kymos.com\/fr\/wp-json\/wp\/v2\/media?parent=37999"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/kymos.com\/fr\/wp-json\/wp\/v2\/categories?post=37999"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/kymos.com\/fr\/wp-json\/wp\/v2\/tags?post=37999"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}